首页> 外文OA文献 >Design, stereoselective synthesis, configurational stability and biological activity of 7-chloro-9-(furan-3-yl)-2,3,3a,4-tetrahydro-1H-benzoepyrrolo2,1-c1,2,4thiadiazine 5,5-dioxide
【2h】

Design, stereoselective synthesis, configurational stability and biological activity of 7-chloro-9-(furan-3-yl)-2,3,3a,4-tetrahydro-1H-benzoepyrrolo2,1-c1,2,4thiadiazine 5,5-dioxide

机译:7-氯-9-(Furan-3-基)-2,3,3a,4-四氢-1H-苯并E Pyrrolo 2,1-C 2,1-C 2,1-C 2,1-c 1,2,4噻二嗪5,5-二氧化物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chiral 5-arylbenzothiadiazine derivatives have recently attracted particular attention because they exhibit an interesting pharmacological activity as AMPA receptor (AMPAr) positive modulators. However, investigations on their configurational stability suggest a rapid enantiomerization in physiological conditions. In order to enhance configurational stability, preserving AMPAr activity, we have designed the novel compound (R,S)-7-chloro-9-(furan-3-yl)-2,3,3a,4-tetrahydro-1H-benzo[e]pyrrolo[2,1-c][1,2,4]thiadiazine 5,5-dioxide bearing a pyrrolo moiety coupled with the 5-(furan-3-yl) substituent on benzothiadiazine core. A stereoselective synthesis was projected to obtain single enantiomer of the latter compound. Absolute configuration was assigned by X-ray crystal structure. Patch clamp experiments evaluating the activity of single enantiomers as AMPAr positive allosteric modulator showed that R stereoisomer is the active component. Molecular modeling studies were performed to explain biological results. An on-column stopped-flow bidimensional recycling HPLC procedure was applied to obtain on a large scale the active enantiomer with enantiomeric enrichment starting from the racemic mixture of the compound.
机译:手性5-芳基苯基噻嗪衍生物最近引起了特别的注意,因为它们表现出一个有趣的药理活性作为AMPA受体(AMPAR)阳性调节剂。然而,对其配置稳定性的研究表明生理条件下的快速对映体。为了提高配置稳定性,保留AMPAR活动,我们设计了新型化合物(R,S)-7-氯-9-(Furan-3-Y1)-2,3,3a,4-四氢-1h-苯并[e]吡咯并[2,1-C] [1,2,4]噻二维嗪5,5-二氧化氮含有吡咯的部分,其与苯并噻嗪核的5-(呋喃-3-基)取代基结合。突出了立体选择性合成以获得后一种化合物的单一对映体。通过X射线晶体结构分配绝对配置。作为AMPAR阳性变构调制剂的单映异构体的活性评估单映异构体的活性的膜片钳位实验表明R立体异构体是活性成分。进行分子建模研究以解释生物学结果。施加柱停止流动的循环回收HPLC程序,以获得大规模的活性对映体,其从化合物的外消旋混合物开始具有对映体富集的致映体富集。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号